OPKO Secures 15% Equity in Nicoya, Bolstering RAYALDEE's Greater China Commercialization
OPK is trading near its 52-week low of $0.977 (14% above the low) on elevated volume (4.0× avg).
Summary
OPKO Health's subsidiary, EirGen Pharma, has amended its commercialization agreement with Nicoya Therapeutics, granting OPKO a 15% equity interest in Nicoya. This strategic move deepens the existing partnership for RAYALDEE, OPKO's approved treatment for secondary hyperparathyroidism, in the significant Greater China market. While the original agreement's $115 million in development, regulatory, and sales-based milestones remain, the new equity stake provides OPKO with a direct financial interest in Nicoya's success. This expansion reinforces Nicoya's commitment to commercializing RAYALDEE in a region with over 20 million adults affected by chronic kidney disease, with regulatory approvals in China expected in 2027. This development is a positive step in OPKO's strategy to extend RAYALDEE's reach into Asia and broaden patient access.
At the time of this announcement, OPK was trading at $1.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $838.2M. The 52-week trading range was $0.98 to $1.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.